97 related articles for article (PubMed ID: 2712112)
1. The development of alpha-emitting radionuclide lead 212 for the potential treatment of ovarian carcinoma.
Rotmensch J; Atcher RW; Hines J; Grdina D; Schwartz JS; Toohill M; Herbst AL
Am J Obstet Gynecol; 1989 Apr; 160(4):789-97. PubMed ID: 2712112
[TBL] [Abstract][Full Text] [Related]
2. Comparison of short-lived high-LET alpha-emitting radionuclides lead-212 and bismuth-212 to low-LET X-rays on ovarian carcinoma.
Rotmensch J; Atcher RW; Hines J; Toohill M; Herbst AL
Gynecol Oncol; 1989 Dec; 35(3):297-300. PubMed ID: 2599463
[TBL] [Abstract][Full Text] [Related]
3. The effect of the alpha-emitting radionuclide lead-212 on human ovarian carcinoma: a potential new form of therapy.
Rotmensch J; Atcher RW; Schlenker R; Hines J; Grdina D; Block BS; Press MF; Herbst AL; Weichselbaum RR
Gynecol Oncol; 1989 Feb; 32(2):236-9. PubMed ID: 2910786
[TBL] [Abstract][Full Text] [Related]
4. Radioimmunotherapy targeting of HER2/neu oncoprotein on ovarian tumor using lead-212-DOTA-AE1.
Horak E; Hartmann F; Garmestani K; Wu C; Brechbiel M; Gansow OA; Landolfi NF; Waldmann TA
J Nucl Med; 1997 Dec; 38(12):1944-50. PubMed ID: 9430475
[TBL] [Abstract][Full Text] [Related]
5. Radon-220 diffusion from 224Ra-labeled calcium carbonate microparticles: Some implications for radiotherapeutic use.
Napoli E; Bønsdorff TB; Jorstad IS; Bruland ØS; Larsen RH; Westrøm S
PLoS One; 2021; 16(3):e0248133. PubMed ID: 33662039
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo studies on the development of the alpha-emitting radionuclide bismuth 212 for intraperitoneal use against microscopic ovarian carcinoma.
Rotmensch J; Whitlock JL; Schwartz JL; Hines JJ; Reba RC; Harper PV
Am J Obstet Gynecol; 1997 Apr; 176(4):833-40; discussion 840-1. PubMed ID: 9125608
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and imaging of 212Pb-TCMC-trastuzumab after intraperitoneal administration in ovarian cancer patients.
Meredith RF; Torgue J; Azure MT; Shen S; Saddekni S; Banaga E; Carlise R; Bunch P; Yoder D; Alvarez R
Cancer Biother Radiopharm; 2014 Feb; 29(1):12-7. PubMed ID: 24229395
[TBL] [Abstract][Full Text] [Related]
8. Significant systemic therapeutic effects of high-LET immunoradiation by 212Pb-trastuzumab against prostatic tumors of androgen-independent human prostate cancer in mice.
Tan Z; Chen P; Schneider N; Glover S; Cui L; Torgue J; Rixe O; Spitz HB; Dong Z
Int J Oncol; 2012 Jun; 40(6):1881-8. PubMed ID: 22322558
[TBL] [Abstract][Full Text] [Related]
9.
Li M; Sagastume EA; Lee D; McAlister D; DeGraffenreid AJ; Olewine KR; Graves S; Copping R; Mirzadeh S; Zimmerman BE; Larsen RH; Johnson FL; Schultz MK
Curr Med Chem; 2020; 27(41):7003-7031. PubMed ID: 32720598
[TBL] [Abstract][Full Text] [Related]
10. Targeted alpha therapy for chronic lymphocytic leukaemia and non-Hodgkin's lymphoma with the anti-CD37 radioimmunoconjugate 212Pb-NNV003.
Maaland AF; Saidi A; Torgue J; Heyerdahl H; Stallons TAR; Kolstad A; Dahle J
PLoS One; 2020; 15(3):e0230526. PubMed ID: 32187209
[TBL] [Abstract][Full Text] [Related]
11. Biological effect of lead-212 localized in the nucleus of mammalian cells: role of recoil energy in the radiotoxicity of internal alpha-particle emitters.
Azure MT; Archer RD; Sastry KS; Rao DV; Howell RW
Radiat Res; 1994 Nov; 140(2):276-83. PubMed ID: 7938477
[TBL] [Abstract][Full Text] [Related]
12. (212)Pb@C(60) and its water-soluble derivatives: synthesis, stability, and suitability for radioimmunotherapy.
Diener MD; Alford JM; Kennel SJ; Mirzadeh S
J Am Chem Soc; 2007 Apr; 129(16):5131-8. PubMed ID: 17394315
[TBL] [Abstract][Full Text] [Related]
13. In vitro killing of melanoma by liposome-delivered intracellular irradiation.
Pikul SS; Parks NJ; Schneider PD
Arch Surg; 1987 Dec; 122(12):1417-20. PubMed ID: 3689118
[TBL] [Abstract][Full Text] [Related]
14. VCAM-1 targeted alpha-particle therapy for early brain metastases.
Corroyer-Dulmont A; Valable S; Falzone N; Frelin-Labalme AM; Tietz O; Toutain J; Soto MS; Divoux D; Chazalviel L; Pérès EA; Sibson NR; Vallis KA; Bernaudin M
Neuro Oncol; 2020 Mar; 22(3):357-368. PubMed ID: 31538194
[TBL] [Abstract][Full Text] [Related]
15. Exploration of a F(ab')
Milenic DE; Kim YS; Baidoo KE; Wong KJ; Barkley R; Delgado J; Brechbiel MW
Cancer Biother Radiopharm; 2018 Jun; 33(5):182-193. PubMed ID: 29916748
[TBL] [Abstract][Full Text] [Related]
16. Skeletal 212Pb retention following 224Ra injection: extrapolation of animal data to adult humans.
Schlenker RA
Health Phys; 1988 Apr; 54(4):383-96. PubMed ID: 3350659
[TBL] [Abstract][Full Text] [Related]
17. Deposition and clearance of 212Pb in humans.
Pillai PM; Paul AC; Bhat IS; Iyer MR; Pillai KC
Health Phys; 1994 Mar; 66(3):343-5. PubMed ID: 8106255
[TBL] [Abstract][Full Text] [Related]
18. An improved generator for the production of 212Pb and 212Bi from 224Ra.
Atcher RW; Friedman AM; Hines JJ
Int J Rad Appl Instrum A; 1988; 39(4):283-6. PubMed ID: 2838433
[TBL] [Abstract][Full Text] [Related]
19. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity.
Rosenblum MG; Verschraegen CF; Murray JL; Kudelka AP; Gano J; Cheung L; Kavanagh JJ
Clin Cancer Res; 1999 May; 5(5):953-61. PubMed ID: 10353726
[TBL] [Abstract][Full Text] [Related]
20. [Effect of irradiation on the ATPase activity of the nuclei and mitochondria of ascitic tumor cells].
Ivashchenko AT; Zhubanova AA
Radiobiologiia; 1976; 16(2):264-6. PubMed ID: 138150
[No Abstract] [Full Text] [Related]
[Next] [New Search]
